Search

First randomized evidence for kinase inhibitor activity in acute myeloid leukemia

Despite the success of tyrosine kinase inhibitors in some forms of leukemias such as chronic myeloid leukemia and acute lymphoblastic leukemia, until now a kinase inhibitor had yet to demonstrate activity in acute myeloid leukemia (AML).

Read more

EHA-AHK Joint Membership

Join EHA and AHK  to receive up to €80 discount on your membershipThe European Hematology Association (EHA) and the Asociacioni i Hematologëve të Kosovës (AHK), have joined forces to offer joint membership to their members.

Read more

EHA-HSH Joint Membership

Join EHA and HSH to receive up to €50 discount on your membershipThe European Hematology Association (EHA) and the Hellenic Society of Haematology (HSH), have joined forces to offer joint membership to their members.

Read more

Overview of EHA's Hemoglobinopathies Initiatives

The EHA Topics-in-Focus Hemoglobinopathies Program  (focus on Sickle Cell Disease) aims to expand awareness and education about these increasingly common genetic diseases in Europe, among healthcare professionals, patients and the general population.

Read more

SWG Educational Activities

2023 meetingsThe following EHA-SWG meetings took place in the past calendar year:

54th General Assembly of ERIC members at ELN Symposium 2023
Mannheim, Germany
April 18, 2023

ERIC/Brazilian CLL Group workshop on biomarkers in CLL
Brasilia, Brazil
May 25–26, 2023

55th General Assembly of ERIC members at…

Read more

SPC Advisory Board, EHA2025 Congress

Current committee members
Lorena Arranz, Norway
Peter Borchmann, Germany
Veronika Buxhofer-Ausch, Austria
Ana Cvejic, Denmark
Matteo Della Porta, Italy
Michael Doubek, Czechia
Andreas Glenthøj, Denmark
Maria Gomes da Silva, Portugal
Julia Hauer, Germany
Daniel Hodson, United Kingdom
Cristina João, Portugal
Sören Lehmann, Sweden
Tamás Masszi, Hungary
Karinna Meijer, The Netherlands
Jamie O'Sullivan, Ireland
Cristina Papayannidis, Italy
France…

Read more